Anil R. Maharaj - Concepedia

Author

Anil R. Maharaj

Clinical Research Institute

Also Known As

Anil Maharaj, Anil R Maharaj, Anil R. MAHARAJ, Anil R. Maharaj, Maharaj, Anil R., Swamy, Geeta K.

Publications

396

Citations

H-Index

Concepts

All Affiliations

Clinical Research Institute Duke University Oregon Health & Science University Lurie Children's Hospital University of North Carolina at Chapel Hill

About

Anil R. Maharaj is an author at Clinical Research Institute specializing in medicine, pharmacology, and pharmacokinetic modeling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	113
2	Public Health	2	2	70
3	Education	1	1	34
4	Engineering	1	1	13
5	Child Development	1	1	14

Anil R. Maharaj

Publications

327

Citations

H-Index

Page 1

	Year	Citations
Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility Anil R. Maharaj, Andrea N. Edginton, Nikoletta Fotaki Pharmaceutical Research NutritionClinical NutritionPediatricsGastroenterologyPediatric Gastroenterology	2015	56
Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019 Anil R. Maharaj, Huali Wu, Christoph P. Hornik, JAMA Pediatrics	2020	47
Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects Anil R. Maharaj, Daniel González, Michael Cohen‐Wolkowiez, Clinical Pharmacokinetics Human GrowthPediatric HematologyImmunodeficienciesPathogenesisImmunology	2017	34
Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials Stephen J. Balevic, Christoph P. Hornik, Thomas P. Green, The Journal of Rheumatology	2020	21
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes Stephen J. Balevic, Daniel Weiner, Megan E. B. Clowse, Lupus Science & Medicine	2022	21
Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children Elizabeth J. Thompson, Huali Wu, Anil R. Maharaj, Clinical Pharmacokinetics Therapeutic Drug MonitoringPharmacokinetic ModelingPharmacodynamicsPharmacological StudyMedicine	2019	20
CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib in a mouse Group 3 medulloblastoma model Olivia Campagne, Abigail Davis, Anil R. Maharaj, European Journal of Pharmaceutical Sciences Neuro-oncologyTranslational PharmacologyMedicineAnti-cancer AgentCns Penetration	2019	20
Population pharmacokinetics of olanzapine in children Anil R. Maharaj, Huali Wu, Kanecia O. Zimmerman, British Journal of Clinical Pharmacology PharmacotherapyPopulation PharmacokineticsPhysiologically-based Pharmacokinetic ModelingPharmacodynamic ModelingPre-clinical Pharmacology	2020	14
Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy Anil R. Maharaj, Huali Wu, Christoph P. Hornik, Journal of Pharmacokinetics and Pharmacodynamics EngineeringPharmacokinetic ModelingMedical StatisticBiomedical ModelingMedicine	2020	13
A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery Kevin D. Hill, Anil R. Maharaj, Jennifer S. Li, Pediatric Critical Care Medicine	2020	13

Page 1